125545 -

The number most commonly refers to BLA 125545 , an FDA Biologics License Application for Retacrit (epoetin alfa-epbx) , which is a biosimilar to Epogen and Procrit used to treat anemia.

: Demonstrated similar pharmacodynamic characteristics and toxicity profiles to the reference product. 125545

#Nursing #Oncology #Nephrology #ClinicalGuidelines #DrugSafety The number most commonly refers to BLA 125545

: A popular Explorer Forum thread (ID 125545) regarding manual transfer case conversions. 125545

📢

#Biosimilars #FDA #Hematology #PharmaNews #HealthcareInnovation Clinical Spotlight: Retacrit (epoetin alfa-epbx)